Blog

The latest thoughts from Medicines Law & Policy partners.

New Database Documents the Power of TRIPS Flexibilities

Medicines Law & Policy has published an on-line database of instances of the use of TRIPS flexibilities in public health contexts, titled the TRIPS...

The People vs. AbbVie

Today, 9 May 2025, is an important day in court for the Dutch Pharmaceutical Accountability Foundation (PAF). In February 2023, PAF started a court...

Human Rights Watch: All governments should endorse the WHO C-TAP Solidarity Call to Action

As the race towards a Covid-19 vaccine continues – with 11 leading candidates in phase 3 clinical trials, 14 more in phase 2 and...

The Italian Exception – A personalised approach to accessing high-priced patented medicines

At the end of March 2017, the Italian Minister of Health Beatrice Lorenzin has authorised the importation of generic medicines. She did this with...

Wrapping up 2023 with some noteworthy medicines, law and policy developments

Welcome to our 2023 end-of-the-year blog, our annual and highly-biased run-through of notable access to medicines events of the year that is about to...

WHO Members meet to finalise the Pathogen Access and Benefit Sharing Instrument

In May 2025, the WHO member states adopted the Pandemic Agreement, but they left the work to establish an instrument for Pathogen Access and...

Written remarks submitted to the OHCHR following the Expert Workshop on the key challenges...

This blog was submitted by Dr. Katrina Perehudoff, Law Centre for Health and Rights at the University of Amsterdam, and Medicines Law & Policy,...

Imagine if health and trade ministers would meet in one room this week

A earlier version of this commentary was published on 28 November 2021 by Barron's. This is a time of missed opportunities. This week, trade ministers...

Medicines price transparency: Ground still left to cover

Parts of this blog were previously published in the Lancet Regional Health Europe Secret medicines prices are hotly debated as European health systems struggle to...

WHO is an essential forum for debates on intellectual property and public health

Recently, Health Policy Watch reported that some European countries at the World Health Organization (WHO) Pandemic Agreement negotiations maintain that intellectual property negotiations belong...